STAT3-silenced human dendritic cells have an enhanced ability to prime IFNγ production by both αβ and γδ T lymphocytes

Immunobiology

Volumn 219, Issue 7, 2014, Pages 503-511

  Sanseverino, Isabella ^a   Purificato, Cristina ^a   Varano, Barbara ^a   Conti, Lucia ^a   Gessani, Sandra ^a   Gauzzi, M Cristina ^a  

^a ISTITUTO SUPERIORE DI SANITÀ   (Italy)

Author keywords

Chemokine; Cytokine; Dendritic cell; RNA interference; STAT3; T helper

Indexed keywords

CARBON TETRACHLORIDE; CCL1 CHEMOKINE; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 23; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; MONOCYTE CHEMOTACTIC PROTEIN 1; STAT3 PROTEIN; TOLL LIKE RECEPTOR; TUMOR NECROSIS FACTOR ALPHA; CYTOKINE; LYMPHOCYTE ANTIGEN RECEPTOR;

ARTICLE; CD4+ T LYMPHOCYTE; CELL EXPANSION; CELL VIABILITY; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DENDRITIC CELL; LYMPHOCYTE DIFFERENTIATION; LYMPHOCYTE PROLIFERATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; TH1 CELL; CELL CULTURE; CELL DIFFERENTIATION; COCULTURE; FLOW CYTOMETRY; GENETICS; HUMAN; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; METABOLISM; MONOCYTE; RNA INTERFERENCE; T LYMPHOCYTE SUBPOPULATION; TIME; WESTERN BLOTTING;

BLOTTING, WESTERN; CD4-POSITIVE T-LYMPHOCYTES; CELL DIFFERENTIATION; CELLS, CULTURED; CHEMOKINE CCL4; COCULTURE TECHNIQUES; CYTOKINES; DENDRITIC CELLS; FLOW CYTOMETRY; HUMANS; INTERFERON-GAMMA; INTERLEUKIN-12; LYMPHOCYTE ACTIVATION; MONOCYTES; RECEPTORS, ANTIGEN, T-CELL, ALPHA-BETA; RECEPTORS, ANTIGEN, T-CELL, GAMMA-DELTA; RNA INTERFERENCE; STAT3 TRANSCRIPTION FACTOR; T-LYMPHOCYTE SUBSETS; TH1 CELLS; TIME FACTORS; TOLL-LIKE RECEPTORS;

EID: 84900404021     PISSN: 01712985     EISSN: 18783279     Source Type: Journal    
DOI: 10.1016/j.imbio.2014.02.012     Document Type: Article

References (34)

1. Alshamsan A., Haddadi A., Hamdy S., Samuel J., El-Kadi A.O., Uludag H., et al. STAT3 silencing in dendritic cells by siRNA polyplexes encapsulated in PLGA nanoparticles for the modulation of anticancer immune response. Mol. Pharm. 2010, 7:1643-1654.
2. Banchereau J., Paczesny S., Blanco P., Bennett L., Pascual V., Fay J., et al. Dendritic cells: controllers of the immune system and a new promise for immunotherapy. Ann. N. Y. Acad. Sci. 2003, 987:180-187.
3. Caccamo N., Sireci G., Meraviglia S., Dieli F., Ivanyi J., Salerno A. gammadelta T cells condition dendritic cells in vivo for priming pulmonary CD8 T cell responses against Mycobacterium tuberculosis. Eur. J. Immunol. 2006, 36:2681-2690.
4. Castanotto D., Rossi J.J. The promises and pitfalls of RNA-interference-based therapeutics. Nature 2009, 457:426-433.
5. Conti L., Casetti R., Cardone M., Varano B., Martino A., Belardelli F., et al. Reciprocal activating interaction between dendritic cells and pamidronate-stimulated gammadelta T cells: role of CD86 and inflammatory cytokines. J. Immunol. 2005, 174:252-260.
6. Dagna L., Iellem A., Biswas P., Resta D., Tantardini F., Fortis C., et al. Skewing of cytotoxic activity and chemokine production, but not of chemokine receptor expression, in human type-1/-2 gamma delta T lymphocytes. Eur. J. Immunol. 2002, 32:2934-2943.
7. Debnath B., Xu S., Neamati N. Small molecule inhibitors of signal transducer and activator of transcription 3 (Stat3) protein. J. Med. Chem. 2012, 55:6645-6668.
8. Dorner B.G., Scheffold A., Rolph M.S., Huser M.B., Kaufmann S.H., Radbruch A., et al. MIP-1alpha, MIP-1beta RANTES, and ATAC/lymphotactin function together with IFN-gamma as type 1 cytokines. Proc. Natl. Acad. Sci. U.S.A. 2002, 99:6181-6186.
9. Eberl M., Roberts G.W., Meuter S., Williams J.D., Topley N., Moser B. A rapid crosstalk of human gammadelta T cells and monocytes drives the acute inflammation in bacterial infections. PLoS Pathog. 2009, 5:e1000308.
10. Esashi E., Wang Y.H., Perng O., Qin X.F., Liu Y.J., Watowich S.S. The signal transducer STAT5 inhibits plasmacytoid dendritic cell development by suppressing transcription factor IRF8. Immunity 2008, 28:509-520.
11. Giacomelli M., Tamassia N., Moratto D., Bertolini P., Ricci G., Bertulli C., et al. SH2-domain mutations in STAT3 in hyper-IgE syndrome patients result in impairment of IL-10 function. Eur. J. Immunol. 2011, 41:3075-3084.
12. Gruenbacher G., Gander H., Rahm A., Nussbaumer W., Romani N., Thurnher M. CD56+ human blood dendritic cells effectively promote TH1-type gammadelta T-cell responses. Blood 2009, 114:4422-4431.
13. Iwata-Kajihara T., Sumimoto H., Kawamura N., Ueda R., Takahashi T., Mizuguchi H., et al. Enhanced cancer immunotherapy using STAT3-depleted dendritic cells with high Th1-inducing ability and resistance to cancer cell-derived inhibitory factors. J. Immunol. 2011, 187:27-36.
14. Kabelitz D., Wesch D. Features and functions of gamma delta T lymphocytes: focus on chemokines and their receptors. Crit. Rev. Immunol. 2003, 23:339-370.
15. Kim C.H., Rott L., Kunkel E.J., Genovese M.C., Andrew D.P., Wu L., et al. Rules of chemokine receptor association with T cell polarization in vivo. J. Clin. Invest. 2001, 108:1331-1339.
16. Kortylewski M., Kujawski M., Wang T., Wei S., Zhang S., Pilon-Thomas S., et al. Inhibiting Stat3 signaling in the hematopoietic system elicits multicomponent antitumor immunity. Nat. Med. 2005, 11:1314-1321.
17. Kortylewski M., Swiderski P., Herrmann A., Wang L., Kowolik C., Kujawski M., et al. In vivo delivery of siRNA to immune cells by conjugation to a TLR9 agonist enhances antitumor immune responses. Nat. Biotechnol. 2009, 27:925-932.
18. Laouar Y., Welte T., Fu X.Y., Flavell R.A. STAT3 is required for Flt3L-dependent dendritic cell differentiation. Immunity 2003, 19:903-912.
19. Li Z., Pradera F., Kammertoens T., Li B., Liu S., Qin Z. Cross-talk between T cells and innate immune cells is crucial for IFN-gamma-dependent tumor rejection. J. Immunol. 2007, 179:1568-1576.
20. Martino A., Casetti R., D'Alessandri A., Sacchi A., Poccia F. Complementary function of gamma delta T-lymphocytes and dendritic cells in the response to isopentenyl-pyrophosphate and lipopolysaccharide antigens. J. Clin. Immunol. 2005, 25:230-237.
21. Melillo J.A., Song L., Bhagat G., Blazquez A.B., Plumlee C.R., Lee C., et al. Dendritic cell (DC)-specific targeting reveals Stat3 as a negative regulator of DC function. J. Immunol. 2010, 184:2638-2645.
22. Munz C., Steinman R.M., Fujii S. Dendritic cell maturation by innate lymphocytes: coordinated stimulation of innate and adaptive immunity. J. Exp. Med. 2005, 202:203-207.
23. Nefedova Y., Cheng P., Gilkes D., Blaskovich M., Beg A.A., Sebti S.M., et al. Activation of dendritic cells via inhibition of Jak2/STAT3 signaling. J. Immunol. 2005, 175:4338-4346.
24. Nefedova Y., Huang M., Kusmartsev S., Bhattacharya R., Cheng P., Salup R., et al. Hyperactivation of STAT3 is involved in abnormal differentiation of dendritic cells in cancer. J. Immunol. 2004, 172:464-474.
25. Onai N., Obata-Onai A., Tussiwand R., Lanzavecchia A., Manz M.G. Activation of the Flt3 signal transduction cascade rescues and enhances type I interferon-producing and dendritic cell development. J. Exp. Med. 2006, 203:227-238.
26. Quah B.J., Warren H.S., Parish C.R. Monitoring lymphocyte proliferation in vitro and in vivo with the intracellular fluorescent dye carboxyfluorescein diacetate succinimidyl ester. Nat. Protoc. 2007, 2:2049-2056.
27. Saito M., Nagasawa M., Takada H., Hara T., Tsuchiya S., Agematsu K., et al. Defective IL-10 signaling in hyper-IgE syndrome results in impaired generation of tolerogenic dendritic cells and induced regulatory T cells. J. Exp. Med. 2011, 208:235-249.
28. Sanseverino I., Purificato C., Gauzzi M.C., Gessani S. Revisiting the specificity of small molecule inhibitors: the example of stattic in dendritic cells. Chem. Biol. 2012, 19:1213-1214. (author reply 1215-1216).
29. Schust J., Sperl B., Hollis A., Mayer T.U., Berg T. Stattic: a small-molecule inhibitor of STAT3 activation and dimerization. Chem. Biol. 2006, 13:1235-1242.
30. Steinman R.M. Dendritic cells: understanding immunogenicity. Eur. J. Immunol. 2007, 37(Suppl. 1):S53-S60.
31. Wang T., Niu G., Kortylewski M., Burdelya L., Shain K., Zhang S., et al. Regulation of the innate and adaptive immune responses by Stat-3 signaling in tumor cells. Nat. Med. 2004, 10:48-54.
32. Wen L., Barber D.F., Pao W., Wong F.S., Owen M.J., Hayday A. Primary gamma delta cell clones can be defined phenotypically and functionally as Th1/Th2 cells and illustrate the association of CD4 with Th2 differentiation. J. Immunol. 1998, 160:1965-1974.
33. Yang L., Carbone D.P. Tumor-host immune interactions and dendritic cell dysfunction. Adv. Cancer Res. 2004, 92:13-27.
34. Yu H., Pardoll D., Jove R. STATs in cancer inflammation and immunity: a leading role for STAT3. Nat. Rev. Cancer 2009, 9:798-809.